Comparison of Haploidentical Bone Marrow versus Matched Unrelated Donor Peripheral Blood Stem Cell Transplantation with Posttransplant Cyclophosphamide in Patients with Acute Leukemia
- 1 February 2021
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 27 (3), 843-851
- https://doi.org/10.1158/1078-0432.ccr-20-2809
Abstract
Background: Post-transplant cyclophosphamide (PTCy) is increasingly being utilized as a principle graft-versus-host disease (GvHD) prophylaxis strategy in allogeneic hematopoietic cell transplantation (allo-HCT). A haploidentical (haplo) or matched unrelated donor (UD) are valid options in the absence of a matched related donor. Experimental design: We compared the outcomes of patients with acute leukemia who underwent haplo bone marrow (haplo-BM, N=401) versus UD mobilized peripheral blood stem cells (UD-PB, N=192) transplantation in the setting of PTCy. Results: The median follow-up duration was 36 months in the haplo-BM group and 16.6 months in the UD-PB group, respectively (p<0.01). Myeloablative conditioning was used in 64.6% and 42.7% of haplo-BM and UD-PB patients, respectively (p<0.01). Cumulative incidence of neutrophil engraftment at day 30 was 87% in haplo-BM versus 94% in UD-PB, respectively (p =0.21). In the multivariate analysis, the risk of grade II-IV acute GvHD (HR=0.53, p=0.01) and chronic GvHD (HR=0.50, p=0.02) was significantly lower in the haplo-BM group compared to the UD-PB group. There was no significant difference between the study groups, with respect to relapse incidence, non-relapse mortality, leukemia-fee survival, overall survival or, GvHD-free, relapse-free survival. Conclusion: The use of a haplo donor with a BM graft resulted in a lower incidence of GvHD compared to a UD-PB stem cell graft in the setting of PTCy for patients with acute leukemia. However, differences in GvHD did not translate into the difference in survival outcomes. Based upon these data, UD-PB or haplo-BM should be considered equally acceptable sources for allo-HCT.Keywords
Other Versions
Funding Information
- None
This publication has 36 references indexed in Scilit:
- Definition of GvHD-free, relapse-free survival for registry-based studies: an ALWP–EBMT analysis on patients with AML in remissionBone Marrow Transplantation, 2015
- Comparison of Outcomes of Hematopoietic Cell Transplants from T-Replete Haploidentical Donors Using Post-Transplantation Cyclophosphamide with 10 of 10 HLA-A, -B, -C, -DRB1, and -DQB1 Allele-Matched Unrelated Donors and HLA-Identical Sibling Donors: A Multivariable Analysis Including Disease Risk IndexTransplantation and Cellular Therapy, 2015
- Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemiaBlood, 2015
- Post-Transplantation Cyclophosphamide for Tolerance Induction in HLA-Haploidentical Bone Marrow TransplantationSeminars in Oncology, 2012
- Unmanipulated Haploidentical Bone Marrow Transplantation and Posttransplantation Cyclophosphamide for Hematologic Malignancies after Myeloablative ConditioningTransplantation and Cellular Therapy, 2012
- High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host diseaseBlood, 2010
- Defining the Intensity of Conditioning Regimens: Working DefinitionsTransplantation and Cellular Therapy, 2009
- Quality of life after allogeneic hematopoietic cell transplantationBlood, 2009
- Nonmyeloablative bone marrow transplantation from partially HLA-mismatched related donors using posttransplantation cyclophosphamideTransplantation and Cellular Therapy, 2002
- Chronic graft-versus-host syndrome in man: A long-term clinicopathologic study of 20 seattle patientsThe American Journal of Medicine, 1980